Sage Capital Advisors llc Buys 1,650 Shares of Johnson & Johnson $JNJ

Key Points

• Sage Capital Advisors LLC increased its stake in Johnson & Johnson by 3.7%, owning a total of 46,599 shares valued at approximately $7.12 million after purchasing an additional 1,650 shares.
• Johnson & Johnson reported earnings of $2.77 per share, surpassing analysts' expectations of $2.68, alongside a revenue of $23.74 billion for the recent quarter.
• The company also declared a quarterly dividend of $1.30 per share, translating to an annualized yield of 2.9%, with a dividend payout ratio of 55.61%.

Sage Capital Advisors llc boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,599 shares of the company's stock after buying an additional 1,650 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Sage Capital Advisors llc's portfolio, making the stock its 15th largest holding. Sage Capital Advisors llc's holdings in Johnson & Johnson were worth $7,118,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Capital A Wealth Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $50,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ opened at $178.10 on Friday. The firm's 50 day simple moving average is $170.81 and its 200 day simple moving average is $161.30. The company has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on JNJ shares. Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.